179 related articles for article (PubMed ID: 30473189)
1. Cystic fibrosis is associated with an increased risk of Barrett's esophagus.
Knotts RM; Solfisburg QS; Keating C; DiMango E; Lightdale CJ; Abrams JA
J Cyst Fibros; 2019 May; 18(3):425-429. PubMed ID: 30473189
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
3. Barrett's esophagus in children with cystic fibrosis: not a coincidental association.
Hassall E; Israel DM; Davidson AG; Wong LT
Am J Gastroenterol; 1993 Nov; 88(11):1934-8. PubMed ID: 8237944
[TBL] [Abstract][Full Text] [Related]
4. LOW PREVALENCE OF BARRETT'S ESOPHAGUS IN A RISK AREA FOR ESOPHAGEAL CANCER IN SOUTH OF BRAZIL.
DE Carli DM; Araujo AF; Fagundes RB
Arq Gastroenterol; 2017 Dec; 54(4):305-307. PubMed ID: 28954045
[TBL] [Abstract][Full Text] [Related]
5. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
6. Screening and surveillance for complications related to gastroesophageal reflux disease.
Spechler SJ
Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
[TBL] [Abstract][Full Text] [Related]
7. Risk factors in the development of esophageal adenocarcinoma.
Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review.
Shaheen N; Ransohoff DF
JAMA; 2002 Apr; 287(15):1972-81. PubMed ID: 11960540
[TBL] [Abstract][Full Text] [Related]
9. Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma.
Wennerström EC; Risques RA; Prunkard D; Giffen C; Corley DA; Murray LJ; Whiteman DC; Wu AH; Bernstein L; Ye W; Chow WH; Vaughan TL; Liao LM
Cancer Med; 2016 Sep; 5(9):2657-65. PubMed ID: 27384379
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.
Gopal DV; Lieberman DA; Magaret N; Fennerty MB; Sampliner RE; Garewal HS; Falk GW; Faigel DO
Dig Dis Sci; 2003 Aug; 48(8):1537-41. PubMed ID: 12924649
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.
Runge TM; Abrams JA; Shaheen NJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):203-31. PubMed ID: 26021191
[TBL] [Abstract][Full Text] [Related]
12. Gastroesophageal reflux and cancer.
Turcotte S; Duranceau A
Thorac Surg Clin; 2005 Aug; 15(3):341-52. PubMed ID: 16104125
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
14. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
15. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
17. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.
Sarr MG; Hamilton SR; Marrone GC; Cameron JL
Am J Surg; 1985 Jan; 149(1):187-93. PubMed ID: 3966636
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA
Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene increases the risk of gastroesophageal reflux disease, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis.
Liu BD; Udemba SC; Saleh S; Hill H; Song G; Fass R
Neurogastroenterol Motil; 2023 Dec; 35(12):e14689. PubMed ID: 37807850
[TBL] [Abstract][Full Text] [Related]
20. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
